No Data
Chengda Pharmaceutical: Report for the third quarter of 2024
Chengda Pharmaceutical (301201.SZ) released its performance for the first three quarters, with a net income of 40.3928 million yuan, a decrease of 33.98%.
Chengda Pharmaceutical (301201.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters is 2...
Chengda Pharmaceutical (301201.SZ): has cumulatively repurchased 2.10% of its shares.
Gelonghui October 10th | Chengda Pharmaceutical (301201.SZ) announced that as of September 30, 2024, the company has repurchased a total of 3,244,700 shares of the company through a repurchase special securities account in a centralized auction trading manner, accounting for 2.10% of the company's total share capital. The highest fill price was 22.21 yuan/share, the lowest fill price was 14.63 yuan/share, and the total trade amount was 57.0616 million yuan (excluding trading fees).
Subdued Growth No Barrier To ChengDa Pharmaceuticals Co., Ltd. (SZSE:301201) With Shares Advancing 42%
Chengda Pharmaceuticals (301201.SZ): At present, the sales price of the company's L-carnitine products is relatively stable, slightly improved compared to the lowest market conditions.
On September 29, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated during a specific research session that the current sales price of the company's L-carnitine products is relatively stable, showing a slight improvement compared to the lowest market price. There is still some uncertainty about the future price trends of related products.
Chengda Pharmaceutical: 2024 Semi-Annual Report
No Data
No Data